Literature DB >> 12427792

Mechanisms of hyperinsulinaemia in Child's disease grade B liver cirrhosis investigated in free living conditions.

A V Greco1, G Mingrone, A Mari, E Capristo, M Manco, G Gasbarrini.   

Abstract

AIMS: Human liver cirrhosis is commonly associated with increased fasting and glucose induced insulin concentrations. However, whether the hyperinsulinaemia is a consequence of increased pancreatic insulin secretion, decreased hepatic insulin removal, or impaired feedback regulation of insulin secretion is still doubtful. To investigate these issues, insulin secretion-during 24 hours of standardised living conditions-insulin sensitivity, and hepatic insulin extraction were assessed in cirrhotic patients compared with matched healthy subjects. PATIENTS: Nine Child's disease grade B cirrhotic patients and seven healthy volunteers, participated in the study. The subjects were studied on two separate days, one for the assessment of insulin secretion during a standardised 24 hour life period (calorimetric chamber), and one for the determination of insulin sensitivity.
METHODS: Insulin secretion rates were reconstructed from plasma C peptide concentrations by deconvolution, and indices of beta cell function were derived using a mathematical model describing the functional dependence of insulin secretion on plasma glucose concentrations. Insulin sensitivity was determined using the euglycaemic hyperinsulinaemic clamp technique.
RESULTS: Cirrhotic patients showed a marked hypersecretory response, both in absolute terms (mean (SEM) 295 (53) versus 138 (11) nmol/m(2), p<0.02), and in relation to glucose (175 (26) versus 57 (5) pmol/min/m(2), p<0.02). In particular, the beta cell dose-response function was shifted upward compared with controls. The sensitivity of insulin secretion to the rate of glucose change was also increased. Insulin sensitivity, markedly reduced in cirrhosis (157 (10) versus 296 (30) ml/min/m(2), p<0.002), was strongly inversely correlated (r=0.89, p<0.002) in these patients with insulin secretion at 5 mM glucose. Insulin clearance and hepatic insulin extraction were not reduced. A frank hypermetabolism with increased lipid oxidation was found in this series.
CONCLUSIONS: This study suggests that hyperinsulinaemia, at least in Child's disease grade B cirrhotic patients, is the consequence of increased beta cell sensitivity to glucose, while hepatic insulin extraction does not seem to play a significant part.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12427792      PMCID: PMC1773476          DOI: 10.1136/gut.51.6.870

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  43 in total

1.  Insulin and glucagon concentrations in portal and peripheral veins in patients with hepatic cirrhosis.

Authors:  A V Greco; F Crucitti; G Ghirlanda; R Manna; L Altomonte; A G Rebuzzi; A Bertoli
Journal:  Diabetologia       Date:  1979-07       Impact factor: 10.122

2.  The euglycemic clamp technique in patients with liver cirrhosis.

Authors:  P Vannini; G Forlani; G Marchesini; A Ciavarella; M Zoli; E Pisi
Journal:  Horm Metab Res       Date:  1984-07       Impact factor: 2.936

3.  Feedback inhibition of insulin secretion is altered in cirrhosis.

Authors:  P Cavallo-Perin; A Bruno; P Nuccio; M Goria; G Pagano; G Lenti
Journal:  J Clin Endocrinol Metab       Date:  1986-10       Impact factor: 5.958

4.  Effects of spontaneous portal-systemic shunting on insulin metabolism.

Authors:  G Smith-Laing; S Sherlock; O K Faber
Journal:  Gastroenterology       Date:  1979-04       Impact factor: 22.682

5.  Glucose clamp technique: a method for quantifying insulin secretion and resistance.

Authors:  R A DeFronzo; J D Tobin; R Andres
Journal:  Am J Physiol       Date:  1979-09

6.  Impaired early insulin response to intravenous glucose in alcoholic liver cirrhosis.

Authors:  J Magnússon; K G Tranberg
Journal:  Scand J Gastroenterol       Date:  1987-04       Impact factor: 2.423

7.  Glucose, insulin and somatostatin infusion for the determination of insulin resistance in liver cirrhosis.

Authors:  A V Greco; A G Rebuzzi; L Altomonte; R Manna; A Bertoli; G Ghirlanda
Journal:  Horm Metab Res       Date:  1979-10       Impact factor: 2.936

8.  Hyperinsulinism of hepatic cirrhosis: Diminished degradation or hypersecretion?

Authors:  D G Johnson; K G Alberti; O K Faber; C Binder
Journal:  Lancet       Date:  1977-01-01       Impact factor: 79.321

9.  Insulin action in cirrhosis.

Authors:  R Taylor; R J Heine; J Collins; O F James; K G Alberti
Journal:  Hepatology       Date:  1985 Jan-Feb       Impact factor: 17.425

10.  Hyperinsulinaemia and insulin resistance of cirrhosis: the importance of insulin hypersecretion.

Authors:  J Proietto; F J Dudley; P Aitken; F P Alford
Journal:  Clin Endocrinol (Oxf)       Date:  1984-12       Impact factor: 3.478

View more
  14 in total

1.  Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study.

Authors:  Lauren N Bell; Jiangxia Wang; Sriya Muralidharan; Sadhana Chalasani; Allison M Fullenkamp; Laura A Wilson; Arun J Sanyal; Kris V Kowdley; Brent A Neuschwander-Tetri; Elizabeth M Brunt; Arthur J McCullough; Nathan M Bass; Anna Mae Diehl; Aynur Unalp-Arida; Naga Chalasani
Journal:  Hepatology       Date:  2012-08-21       Impact factor: 17.425

Review 2.  Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance.

Authors:  Christoph G Dietrich; Oliver Götze; Andreas Geier
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

3.  Hepatogenous Diabetes - A Report from Central India.

Authors:  Praveen Vasepalli; Mohd T Noor; Bhagwan S Thakur
Journal:  J Clin Exp Hepatol       Date:  2021-08-25

Review 4.  Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management.

Authors:  Diego Garcia-Compean; Joel Omar Jaquez-Quintana; Jose Alberto Gonzalez-Gonzalez; Hector Maldonado-Garza
Journal:  World J Gastroenterol       Date:  2009-01-21       Impact factor: 5.742

5.  Plasma betatrophin levels in patients with liver cirrhosis.

Authors:  Maria Teresa Arias-Loste; Maria Teresa García-Unzueta; Susana Llerena; Paula Iruzubieta; Angela Puente; Joaquín Cabezas; Carmen Alonso; Antonio Cuadrado; José Antonio Amado; Javier Crespo; Emilio Fábrega
Journal:  World J Gastroenterol       Date:  2015-10-07       Impact factor: 5.742

6.  Decreased expression of insulin and increased expression of pancreatic transcription factor PDX-1 in islets in patients with liver cirrhosis: a comparative investigation using human autopsy specimens.

Authors:  Masahiro Sakata; Akihiko Kawahara; Takumi Kawaguchi; Jun Akiba; Tomoki Taira; Eitaro Taniguchi; Mitsuhiko Abe; Hironori Koga; Masayoshi Kage; Michio Sata
Journal:  J Gastroenterol       Date:  2012-07-12       Impact factor: 7.527

7.  Differential patterns of insulin secretion and sensitivity in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease versus patients with type 2 diabetes mellitus alone.

Authors:  Shang-Yu Chai; Xiao-Yu Pan; Ke-Xiu Song; Yue-Ye Huang; Fei Li; Xiao-Yun Cheng; Shen Qu
Journal:  Lipids Health Dis       Date:  2014-01-07       Impact factor: 3.876

Review 8.  Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management.

Authors:  Maja Cigrovski Berkovic; Lucija Virovic-Jukic; Ines Bilic-Curcic; Anna Mrzljak
Journal:  World J Gastroenterol       Date:  2020-06-07       Impact factor: 5.742

9.  Cirrhosis of Liver and Diabetes Mellitus: The Diabolic Duo?

Authors:  Thazhath Mavali Ramachandran; Aninchent Harayil Rajan Rajneesh; George Sarin Zacharia; Rajendran P Adarsh
Journal:  J Clin Diagn Res       Date:  2017-09-01

10.  Insulin resistance in euglycemic cirrhosis.

Authors:  Amitava Goswami; Narendra Bhargava; Sunil Dadhich; Ganaraj Kulamarva
Journal:  Ann Gastroenterol       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.